Open Label Continuation Study of TRC105 for Patients Who Have Completed a Prior TRC105 Trial
An Open Label Continuation Study of TRC105 Therapy for Patients Who Have Completed a Prior TRC105 Trial and Are Judged by the Investigator to Have the Potential to Benefit From Continued TRC105 Therapy
Sponsor: Tracon Pharmaceuticals Inc.
Listed as NCT02354612, this observational or N/A phase trial focuses on Solid Tumors and remains ongoing. Sponsored by Tracon Pharmaceuticals Inc., it has been updated 10 times since 2026, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
No Longer Available
-
Jul 2024 — Sep 2024 [monthly]
No Longer Available
-
Mar 2021 — Jul 2024 [monthly]
No Longer Available
Status: Completed → No Longer Available · Phase: PHASE1_PHASE2 → None
-
Jan 2021 — Mar 2021 [monthly]
Completed PHASE1_PHASE2
-
Nov 2019 — Jan 2021 [monthly]
Completed PHASE1_PHASE2
Status: Enrolling By Invitation → Completed
▶ Show 5 earlier versions
-
Dec 2018 — Nov 2019 [monthly]
Enrolling By Invitation PHASE1_PHASE2
-
Nov 2018 — Dec 2018 [monthly]
Enrolling By Invitation PHASE1_PHASE2
-
Jun 2018 — Nov 2018 [monthly]
Enrolling By Invitation PHASE1_PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Enrolling By Invitation PHASE1_PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Enrolling By Invitation PHASE1_PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Tracon Pharmaceuticals Inc.
For direct contact, visit the study record on ClinicalTrials.gov .